Description: 4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Home Page: www.4sc.de
Fraunhoferstrasse 22
Planegg,
82152
Germany
Phone:
49 89 700763 0
Officers
| Name | Title |
|---|---|
| Dr. Jason Loveridge B.Sc., B.Sc, Ph.D., FRSM | Chairman of Management Board, CEO & MD |
| Ms. Anna Niedl Ph.D. | Corp. Communications & Investor Relations Officer |
| Dr. Susanne Danhauser-Riedl M.D. | Chief Medical Officer |
| Dr. Frank Hermann M.D. | Chief Devel. Officer |
| Ms. Larissa Stuttem | Team Assistant |
Exchange: XETRA
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9737 |
| Price-to-Sales TTM: | 54.567 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 33 |